Exploring drug use in older adults: APSAD 2024
Burnet partners with Atomo to develop Australia’s first syphilis self-test
Hepatitis C treatment in pharmacies could boost diagnosis and cure rates
Urgent and equitable action needed to prevent mpox becoming the next pandemic emergency
Research Reports + Policy Briefs
IMPACT Magazine
Events
Research Articles
How Science Matters Podcast
Study at Burnet
Stellabody®: A novel hexamer-promoting mutation for improved IgG potency
Dynamic nucleolar targeting of dengue virus polymerase NS5 in response to extrac...
20-year trends in Australian methamphetamine-related deaths, 2001-2020.
Overcoming disparities in hepatocellular carcinoma outcomes in First Nations Aus...
Vaccines
Diagnostics
Therapeutics
Antibody Platforms
Australia
Papua New Guinea
Myanmar
People of Burnet
Leadership
Burnet Partners
Board Members
Current Appeal
Monthly Giving
Trusts + Foundations
Corporate Supporters
Giving in Wills + Bequests
Supporter Stories
About Us
Careers
History
Annual + Financial Reports
Burnet Institute is developing biologic and small molecule therapeutics that have potential application in women's health, infectious disease & immunological conditions.
Find us at BIO 2024 this June.
In collaboration with Monash Institute of Pharmaceutical Sciences (MIPS), we are developing next-gen...
A small molecule therapeutic to potentially combat a variety of conditions affecting women’s sexual ...
A potentially broad spectrum Fc-fusion protein to treat SARS-CoV-2, comprising ACE2 (SARS-CoV-2 rece...